๐
DHR Q1 2026 Earnings Call
April 21, 2026 at 12:00 AM
๐
Company
DHR
Quarter
Q1 2026
Date
April 21, 2026 at 12:00 AM
Speakers
1
Word Count
~8,128
Transcript Content
Operator
Thank you. If you'd like to ask a question, please press star 1 on your keypad. To leave the queue at any time, press star 2. Once again, that is star 1 to ask a question. And our first question will come from Michael Reisken with Bank of America. Please go ahead. Michael Ryskin (Analyst โ Bank of America): Thanks for taking the question. Congrats on the result, Brian, I want to ask a little bit on that progression through the year. As we look at, you know, 1Q, you guys at 0.5%. I'm back into something like 2% core growth in the second quarter, given the various segments. I think that's what the low single digit implies. So you've got a little bit of acceleration in the second half of the year. Can you just talk to, you know, what's driving out across the segments? I think you're lapping, obviously, some of the respiratory headwinds and some of the outbound and GDP, but just confidence in the rest of the business to get that second-half ramp and sort of the progression that's implied in the guide through the year. Rainer Blair (CEO): Good morning. Well, there's certainly a lot going on in the world today, but as we've said, we're focusing on controlling what we can control, and there's really no change to how we view the progression throughout the year that we laid out in January. in January we said there three things really needed to happen to support the ramp throughout the year and all three of those things played out as we expected or actually even a touch better in q1 and we feel good about the balance of the year and here's why in diagnostics that China diagnostic policy headwinds plant are playing out as we expected and actually patient volumes are higher we also saw a good momentum across the rest of diagnostics which showed another quarter of mid single digit growth without china and respiratory and while respiratory was a touch softer we continued to take share and our core molecular business grew mid-team so you know we expect our broader dan her portfolio compensates for the touch of softness that we saw there in respiratory but the quarter also demonstrated strong high single-digit EPS growth even if respiratory was a little bit softer so those are some important proof points here around the resilience of our portfolio in the work that we're doing now if you think about bioprocessing you know here we see strong underlying commercial biologic drug production continue and it drives strength in consumables and notably we're really encouraged to see improvement in our equipment order book with over 30 percent year-over-year growth now turning to life sciences and the progression there both china and life science consumers consumables globally performed better than we expected and that includes growth at abcam and aldebaran which is really encouraging and we saw broad stabilization in our life science end markets with pockets of Matt McGrew (CFO): improvement so we're also seeing better funnel activity there as a result so all in look we feel really good about how we started the year and we believe this momentum continues and my baby just to give some some details around the numbers and specifics here in the progression so the way we're thinking about in this core growth, low single digits in the first half of the year, sequential improvement from Q1 to Q2, you see this reflected in the Q2 guide. Together, the headwinds that we've talked about, China diagnostics, respiratory, so the constant life sciences, they're collectively about a 300 basis point, maybe in a little bit higher impact in the first half of the year. These essentially go away by the end of the year, and why we believe we'll execute for in that mid-single-digit range. So, for the purpose of the guide, the way we've laid it out is we're not really assuming any improvement in our end markets back to the year at that mid-single digits, and that's why we feel comfortable about that progression through the year. Michael Ryskin (Analyst โ Bank of America): Both of those super helpful answers. And let me squeeze a follow-up on that, on the bioprocess specifically, like you talked or strength in consumables, the 30% or greater than 30% equipment order book. It doesn't sound like you're assuming any of that will come through later this year, or could you see some benefit in the fourth quarter? Should that inform how we think about equipment growth next year? And just sort of how do we take those endpoints, those data points of, you know, consistent high single-digit consumables and order book turning to think about BP later this year and into 2027? Rainer Blair (CEO): Well, we continue to see that strength in consumables, and so we see that progressing through the year consistently. Equipment, what we're seeing there in the order book, certainly underwrites and reaffirms the year-over-year improvement that we expected. Recall last year we were down double digits. This year the guide assumes that we're flat on equipment. But we do like the activity levels here in equipment. And, you know, that marker of 30% year-over-year growth is an important one that is certainly supportive of the out years. And we'll have to continue to see how customer readiness plays in here. Sometimes these equipment orders come and, you know, it gets to be a little bit lumpy as customer readiness is a real important factor here as to when you actually end up recognizing the revenue. So we certainly see the guide underwritten here going forward, and we think positively about what this means, certainly for the out years.
Operator
Our next question will come from B.J. Kumar with Evercore ISI. Please go ahead. B.J. Kumar (Analyst โ Evercore ISI): Morning, B.J. Very good morning to you, Reiner. I want to pass along my congratulations to Matt Cusino and Rachel. Good to have you both on the call. Reiner, maybe my first one for you on your comment around Massey acquisition. I think initially when people saw the deal, it was a little confusing. People thought this was a MedTech deal. But maybe just walk us through on this strategic rationale. You know, I think you guys mentioned call point synergies between Brady Armiver and Massimo. My understanding is Massey, some of their tech boards, they also perhaps trade-toe players like Philips, G Healthcare. So, you know, how do you see the call point synergies and, you know, potential for DBS driving high signals ROI for the business? Rainer Blair (CEO): Thanks, DJ. Look, we see the Massimo transaction as a very typical Dan or her deal. And by way of update, you know, the process continues to progress well there, and we're excited to get the Massimo team on board. So, all things are positive in that regard. And, look, we've been following Massimo for over a decade based on the learnings that we had with Radiometer, which is really our diagnostics acute care strategy where, you know, we believe that Massimo is a mission-critical player, differentiated technology, all the things that we like to see when we talk about our three-dimensional acquisition framework. This is a great end market with long-term secular growth drivers. Two, this is the premier asset in pulse oximetry and other applications in acute care diagnostics. It's supportive of what we're doing at Radiometer. In fact, there's geographic synergies as well as NASIMO is a little stronger than Radiometer in the U.S. and that reverses as you think about Europe. So those are all very positive. And really, these solutions sit next to each other here in these acute care settings. So, to your call point synergies, they are significant and they are direct synergies as well. And then I'll also add from a financial profile, this is a transaction that's accretive at all levels, whether it's growth, whether it's gross margins or operating margins. And at the same time, we've been able to identify some pretty significant value reserves here to help us drive that return on invested capital to that high single-digit ROIC in year five. Matt McGrew (CFO): And, D.J., just to follow up, I mean, Ryder talked about some of the synergies here, but what we outlined here a couple months ago when we announced the deal is we expect So with cost and revenue synergies, $125 million of cost synergies realized by year five, call it 50 million of that is on the gross margin side, 50 million on the OPEC side, and about 25 million of public company costs. And then about 50 million of revenue synergies trying to outline some of the opportunities there where you can probably help Massimo through her diagnostics platform get stronger and positioning around the IDNs or integrated delivery networks, and then there's probably some opportunity for Massimo to help us, including Radiometer in the U.S. So I'm really excited, as Rhonda said, to get the team on board here later this year. B.J. Kumar (Analyst โ Evercore ISI): That's fantastic. Hey, Matt, maybe my second one was on margins. I think typically you guys have some seasonality, Q1 to Q2 on the rest of the Cori, but I just feel like second quarter, maybe margins, the step down, it's a little bit more than what we saw in the last two years. Maybe just talk about sequential margins. Just getting Q1 was such a, you know, such a good execution from a margin standpoint. Matt McGrew (CFO): Yeah, sure, Vijay. I mean, like you mentioned, I mean, we typically see a several hundred basis points step down and operating margins, Q1 to Q2. that's written by that typical step-down, seasonal step-down in respiratory. There's probably a little bit more FX impact here, Q2 versus Q1, just given where the dollar has moved over the last couple of months. And then also, I think given the Q1 beat here, we wanted to take some of that beat, accelerate some growth investments from the second half of the year into Q2. So the way we're thinking about it is we just did what we're expecting, made the high single-digit earnings growth in the first half of the year all in, And that puts us on the right path here for the rest of the year as we go forward. Thanks, guys. Thanks, EJ.
Operator
Thank you. Our next question will come from Scott Davis with Melius Research. Please go ahead. Rainer Blair (CEO): Good morning, Scott. Matt McGrew (CFO): Hey, good morning, guys. Good morning, Reiner. Glad to hear your voice, Matt and Rachel. Congrats. Hey, guys. Rainer Blair (CEO): Can you talk a little bit about โ yeah, good morning. can you talk about raw raw materials just resins costs so with the spike in oil prices and the associated increases in petrochemical derivatives we have our eyes firmly focused on what's going on there and and while we see some of that pressure out there it hasn't been really meaningful yet as it relates to our own cost position. That said, we're incredibly vigilant there and leveraging the Danaher business system as well as our contract positions to mitigate any pressures that are there. And I'll just say, as you would expect of us, Scott, here with the Danaher rigor, we We, every month, with every business, every operating company, work through the entire P&L to understand what measures we're taking and how raw material volatility might affect the business. So we are all over that proactively, and to date, we haven't seen any meaningful pressure there. Matt McGrew (CFO): And same with Middle East, Reiner? Rainer Blair (CEO): Well, the Middle East is really driving a good part of that pressure, Scott, in the sense that the volatility in oil prices are driving that. In terms of supply from the Middle East, that really doesn't affect us. So our supply chain is not directly affected by the Middle East, but, of course, the indirect effects that you're alluding to here are something that we have to address head on. Matt McGrew (CFO): Okay. Thank you, guys. Rainer Blair (CEO): Thanks, Scott.
Operator
Thank you. Our next question will come from Jack Meehan with Nephron Research. Please go ahead. Jack Meehan (Analyst โ Nephron Research): I'm Jack. Good morning, guys. One of the big topics in the market at the moment is AI. I wanted to get your thoughts on that. The first question is, as you look across the business segment, how do you think AI is influencing customer spending behavior? You referenced bioprocessing, which could be a beneficiary. I was curious what you also thought about lifetime services and diagnostics. Any signs have increased or reduced spending in the business? Rainer Blair (CEO): So let me get started here. You were a little bit in and out in terms of the volume on the question, but I think I've got it. Let me start with the conclusion here, which is we think AI is going to be a growth accelerator for the pharma and biotech industry, both in the near and in the long term. And the reason for that is we think that AI will accelerate the drug development and commercialization flywheel and result in better development pipeline yields. So, as you know, the average yield in the drug development pipeline today is just above 10%. There's an enormous opportunity here to improve the yield of the pipeline and to accelerate the biopharma flywheel along with the flywheels of life science tool providers like ourselves. And so this improved yield drives both growth and profitability and reinvestment in the pharma industry. industry. And that, of course, in turn drives more investment into discovery, including wet lab validation, development in the clinic, as well as commercial drug manufacturing. So in the short term, what we're seeing actually is incremental more demand, which we expect to accelerate in the building of biologic models. Autonomous science is the current buzzword that refers to the building of biologic models and of course that requires automation which was very well represented in it requires more analytical instruments and it requires more reagents as well so that's the short-term impact as this practically new market segment of autonomous science starts to play out here and that plays out first in discovery and then continues to accelerate through the development pipeline and of course we're very well positioned here with our life science tools. I mentioned automation analytical instruments that, of course, increasingly are AI-enabled, the reagents that support all of those models going forward. And that's a several-year driver. These biologic models are in a single-digit percentage of information coverage required, very different than large language models. these biologic models require significantly more information in order to become general use type of models. So that's the short term. And as I indicated, then, in the long term, what we're going to see is the cycle time of pharma development being compressed and the hit rate, i.e., the yield, to be increased. And that flywheel is going to be very good for patients. It's going to be very good for the pharma industry. and those partners like ourselves that support that industry. Now, as you think about that, going through development, Jack, sorry, just to finish up, of course, these more commercialized drugs means more business for our bioprocessing business. We're the best position there with the broadest and deepest portfolio. I talked about the innovations that we're launching there. And then lastly, a lot of these drugs are going to be more sophisticated. They are going to require more sophisticated, more accurate diagnostics. If they're not personalized diagnostics, they will require near-personalized diagnostics to come online. So, again, I start with the conclusion, which is AI is a tailwind in the short and in the long term, and it's healthy for all market participants, and, of course, we're very well positioned there. Jack Meehan (Analyst โ Nephron Research): Excellent. So, yeah, it's clear there's a lot of exciting things across the business. Maybe for you, Ryan, or for Matt, just extending that from a DBS perspective, are you seeing any tangible signs of productivity benefits from AI in the business? Any cost savings or revenue charts that you'd be comfortable sharing at this point? Rainer Blair (CEO): We are getting to the point, Jack, where DBS and AI are synonymous to us in terms of accelerating cycle times and driving efficiencies, and we bring those together. So, we talk about AI-enabled DBS and DBS-enabled AI in one sentence, and that will continue to drive efficiency. Let's just tee it up this way. As you think about the conversation I just had as it relates to the pharma development pipeline, think about Danaher's flywheel also being accelerated by AI-enabled DBS. That will result in more and better products that are A&I-enabled. It's going to result in lower costs that we gain through efficiencies. And together, that's going to drive growth and earnings expansion going forward. Jack Meehan (Analyst โ Nephron Research): Thank you. Rainer Blair (CEO): Thanks, Jack. Doug Schenkel (Analyst โ Wolfe Research): Thanks, Jack.
Operator
Thank you. Our next question will come from Tycho Peterson with Jeffries. Please go ahead. Tycho Peterson (Analyst โ Jefferies): Morning, Tycho. Morning. Reiner, I want to go back to bioprocessing. You know, I appreciate you touched on order trends and, you know, how that may translate to revenues. But I'm wondering if you can unpack, you know, a little bit more of what you're seeing, you know, pharma versus biotech versus CDMOs. Secondly, are you seeing any replacement cycle demand? We've heard about, you know, replacement cycle heating up a little bit as we've done some checks. And then how are you sizing the China opportunity in biotech? I think it was around a billion and 1.3 billion if you go back a couple years. But how are you sizing that opportunity today? Rainer Blair (CEO): Thanks, Tycho. So, well, starting with China here where you ended up, China continues to be in recovery mode. We're very encouraged with what we saw in China here in the first quarter with double-digit growth in the bioprocessing business. The China biologics and driven by the biotech market that you referred to is accelerating. The monetization of the therapies being developed there has been resolved with both the license deals that you see with multinationals, but also the stock exchange and IPOs once again functioning properly. And so we expect that to continue to be a growth driver here as we get back to normality. So, is the original $1.3 billion that we saw there at the peak in the cards? Well, look, we're on the way to improve markets. We're happy to see that. We want to get through 2026 here and see that continued positive progression on China. As it relates to, you know, the equipment orders that we saw there, We think that continues to be very constructive to our hypothesis around 2026 and beyond. Both the funnel activity is encouraging, as well as you saw that year-over-year orders growth. As I said, that underwrites how we're thinking about the year here. And let's see how the next quarters progress to see whether that has any impact here in 2026. but certainly it will as we go beyond 2026. Tycho Peterson (Analyst โ Jefferies): And then maybe just shifting over to life science, you know, encouraging to see the turn there. I think you, you know, talked about approved funnel activity, obviously Aldebaran. I think coming out of 4Q, you hadn't assumed Aldebaran would grow in the first half of the year. So that's encouraging to see. And then, you know, A&D consumables a bit better for ABCAM. I guess, you know, maybe just talk a little bit about where you're feeling better as we think about the remainder of the year for that life science business. Rainer Blair (CEO): So in life sciences, and you just touched upon it, in the consumables area, we expect it to be slightly down here in the year, albeit off of an improved second half of the I think as we go forward, we see positive growth for our life science consumables business here for the full year. While that might be a little bit lumpy as we go through the next quarter or two, we do expect that to go from slightly negative to slightly positive, and that's quite encouraging. And then we also saw China. China is continuing or, let's say, starting up and investing again, also in life science instruments. That was nice to see here in the quarter, and the funnels there continue to be quite constructive. So all in all, we see some nice pockets of improvement there. Pharma was strong, continued to improve here quarter over quarter. Clinical was robust. the applied markets are playing out as we thought, only academic remains a bit muted albeit stable. So we're encouraged here by what we saw in life sciences in the first quarter and expect that to play out positively for the rest of the year. Okay thank you.
Operator
Thank you. We'll come from Casey Woodring with JP Morgan. Please go ahead. Casey Woodring (Analyst โ JPMorgan): Okay great yeah morning thanks for taking my questions. So it's nice to see the greater than 30% file processing equipment order growth in the quarter, but assume that number is probably coming off of a lower base year-on-year. So can you just give us any sense of what orders grew sequentially in 4Q or what book to bill was in the quarter, you know, any sense of how those came in relative to your expectations? And then we'll also be curious to hear more about the Brownfield versus Greenfield investment dynamic that you talked a little bit about. You highlighted Brownfield investments are flowing through and said greenfield would be expected to follow, just curious on your expectations of when we could potentially see those greenfield orders start to flow through. Is that something you wouldn't be surprised to see in the second half? Yeah. Rainer Blair (CEO): So, Casey, the first quarter orders growth was the first positive year-over-year orders growth that we have seen in nearly two years. So, by definition, then, the comp is a little bit lighter. But if we look at the activity level here, a quarter over quarter, while the first quarter orders were actually down a little bit sequentially, that's absolutely expected as a result of the first quarter activity seasonality step down. So, we always see that, and that's why that year-over-year comparator is so important. but at the same time we see our funnel activity continue to be robust on the equipment side so I wouldn't focus as much on that as the data point that we're seeing year-over-year growth now whereas previously it was sequential growth so very encouraged as I mentioned earlier about what we're seeing in the equipment orders some of those orders are starting to get a little bit larger And that dovetails into the second part of your question. So we see equipment orders growth in the funnel activity driven by two different dimensions. The first one is that we have seen underinvestment in the industry for the last two years as it relates to capacity. Despite the fact that we've seen very robust growth, our consumables business demonstrates that the activity level has been robust and strong here for the last couple years now and and and that means that capacities require expansion we have biosimilars coming on the market we have new compounds coming onto the market and of course a little bit of underinvestment so that really explains what we're seeing there both in terms of brownfield investments as well as the one or the other additional line or or even greenfield investment the second vector is this reshoring dynamic and and here we see again increased dialogue already some funnel activity even the one or the other order here from brownfield expansions as it relates to reshoring so we're really encouraged by what we're seeing here on On the equipment side, as I say, it underwrites our hypothesis for the year, and it further supports how we think about the equipment progression and the bioprocessing strength beyond 26. Casey Woodring (Analyst โ JPMorgan): That's helpful. If I can just squeeze one more in quickly. Ryan, you talked about solid growth across non-respiratory within diagnostics, and you held the guide for the year in diagnostics even with the lower respiratory number. So maybe can you just walk through what exactly is offsetting that lower respiratory number for the year and what's getting better in that non-respiratory piece that's enabling you to hold the guide? Thank you. Rainer Blair (CEO): Well, there's a couple things going on there, Casey. The first one being that, you know, we continue to take share at Cepheid in the core business, which is very important, and our hypothesis around Cepheid continues to play out. We're launching new assays there. the gastrointestinal GI panel is doing very well our MVP panel is doing very well so even within Cepheid you see strength here that is playing out and then in our non respiratory business and and you take out China we continue to receive mid single-digit growth there with our innovation strategy playing out we've launched at Beckman Coulter an entire series of new instruments and equipment there, none more important than the high resolution GXI 9000, which opens up entirely new pieces of menu to us. We've closed that blood virus menu gap. And of course, we have that fast track device for certification for Alzheimer's disease testing. So, we continue to see positive momentum there. And then we haven't even talked yet about the implications of Massimo joining the portfolio. So then the last point I would make, as it relates to China, VBP and the guideline discussions that we have, we're in very strong dialogue with the China government here, and we've had visibility of what has been going on there for some time. So we feel good about our assumptions around the $75 million to $100 million headwind there in China, And that's only been validated by what we've seen in China here in the first quarter, even if the patient volumes were actually a little higher. Matt McGrew (CFO): Great. Thank you so much. Thanks, Jason.
Operator
Thank you. Our next question will come from Dan Brennan with TD Cowan. Please go ahead. Dan Brennan (Analyst โ TD Cowen): Great. Thanks for the questions. Good morning, Reiner and Merritt and Rachel. Maybe just on M&A, you know, the balance sheets and Gitche, Post, Massey, just wondering how you're prioritizing M&A today if you look at your three business segments. You know, where do you see the biggest opportunities? It's a question we get a lot from investors. And kind of what does the funnel look like? You know, do you think you could see another sizable deal this year? Rainer Blair (CEO): We're very encouraged by what we're seeing in the funnel. As you know, multiples have come in, and our three-vector filter on M&A is, you know, becoming more and more relevant here. As we've talked about so often, one, our bias to capital deployment is M&A. to we will not compromise on our discipline as it relates to being in the right-hand market with the secular growth drivers that we like to see to having a premier asset that has defensible positions or the opportunity with real value reserves. And then lastly, of course, the financial model has to work. And what we've been seeing in the current context is that the financial models are becoming more viable so just to reiterate one the Massey deal for us was one that we have envisaged for a long time and the timing of that deal is defined ultimately by the processes that are run and we were ready with the balance sheet and the point of view to execute on that deal and we're really excited about that and that fits right into our acute care strategy now what What it's not is a broader investment thesis around the broader medtech market on the one hand, but on the other hand, it is also not indicative of our point of view as it relates to life sciences, diagnostics, and bioprocessing. We see here plenty of opportunity to deploy capital and are fully prepared to do that as the opportunities arise. Matt McGrew (CFO): And, Dan, I mean, from a balance sheet perspective, post-close of Massimo will go to about two and a half turns, net debt, EBITDA, given our strong free cash flow, $5 billion-plus per year, as well as EBITDA generation. I mean, this leverage will come down fairly quickly. Dan Brennan (Analyst โ TD Cowen): So, it gives us the ability to remain active on the M&A front even in the near term, so feel good about how we're positioned from a balance sheet side of things. yeah that sounds great um maybe back to a question i think mike started off the call with you know your core group is anchored at three percent this year i think consensus is around five next year so assuming the consensus is in the right zip code can you just walk through the key leverage to generate five percent growth next year including what could push down or higher up in your lrp towards that high single digit level thank you yeah yeah i mean it's april of 2026. Matt McGrew (CFO): I think we're a little bit too early to talk about 27, but I'll just kind of go back to what we talked about with Mike here at the beginning of the call, where we're talking about low single-digit core growth in the first half of this year. There's about 300 basis points or a little bit more of impact from the headwinds that we talked about. China diagnostics, respiratory, the constant life sciences. That's why we feel comfortable about exiting Q4 or in that mid-single-digit range, and really getting through those headwinds enable us, without really any improvement on the end market side, to get comfortable into that mid-single-digit range. Great. Thanks, Matt.
Operator
Thank you. Matt McGrew (CFO): Thanks, Ben.
Operator
And our last question will come from Doug Sinkel with Wolf Research. Please go ahead. Doug Schenkel (Analyst โ Wolfe Research): Hey, good morning, everybody. Thank you for checking the questions. Matt, maybe a follow-up on your comments there at the end in response to Dan's question. What gets you to the high end of guidance for the year? Is it really just what you described there, moving past the headwinds and maybe those actually reversing in a more robust way than we're seeing right now? And maybe related to that, you know, as we sit here today, would you recommend that we essentially stay at the lower end of the guidance range for the year until we see some improvement, both in terms of those headwinds abating and maybe some improvement in end markets? So that's the first topic. And then another follow-up on M&A, just to be clear there, from a readiness standpoint, could you do something in any segment as we see here today or given the pending NASIMO deal, you know, would it be less likely that you would do something in diagnostics, you know, as you're in the process of integrating that business or getting ready to integrate that business? Thank you. Matt McGrew (CFO): Thanks, Doug. So, like we talked about in January, continue to anchor to that, the low end of the 2026 core growth guide for planning purposes. In terms of what gives us to the higher end of the guide, I think you need to see a couple things, Doug. First, you need to see some further improvement across the life sciences and markets. I think we're encouraged by what we saw here in Q1, but, you know, we need to see some of those policy headwinds further abate, especially in the U.S. and what we've seen there. I think China, good start to the year, but we need to see further growth acceleration as well. And then on the biotech funding side, again, starting to see some improvement, but we want to see that funding turn more quickly into orders. I think the second thing about processing, we probably need to see it a little bit better than the high single-digit growth. We need to accelerate on the consumable side as well as get that equipment growth going here. Again, encouraged by the order patterns, but probably need to see it move a little bit quicker. And then the other thing here that we talked about on the respiratory side, we probably need to see a little bit above normal respiratory season to finish the year here in NQ4 back to that kind of endemic $1.8 billion rate that we see going forward. So I think all I know, we're encouraged by the start of the year. We're already at 3% ex-respiratory today and encouraged to see some of the underlying trends as we talked about. Rainer Blair (CEO): And Doug, as it relates to M&A, we have both the balance sheet capacity as well as the leadership bandwidth here to execute additional acquisitions in any of the three segments and feel very good about how we position our talent and develop that talent in order to be able to do that we've now reached our allotted time for questions so I'll turn the call back over to management for any additional or closing remarks no perfect that is all we have you can reach us with questions today Rachel Vatnsdal (Head of Investor Relations): Thank you so much for joining. Thanks, everyone.
Operator
Thank you, ladies and gentlemen. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.
Need more earnings data?
Explore more earnings information and financial data for DHR
Transcript sourced from Financial Modeling Prep (FMP)